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ABSTRACT 
 
Importance: To investigate the safety, effectiveness and follow up rates after transscleral diode 
laser cyclophotocoagulation as primary treatment for seeing eyes with primary open angle 
glaucoma in Bauchi, Nigeria.  
Background: There is a high prevalence of primary open angle glaucoma in Africa where 
adherence to medical treatment and acceptance of surgery are poor.   
Design: Prospective case series  
Participants: New glaucoma patients where surgical intervention was recommended. 
Methods: A diode 810nm laser G-probe was used under retrobulbar anaesthesia to deliver 
approximately 20 shots for 2000ms, titrating the power. If both eyes were treated the first treated 
was the study eye. Repeat treatment was offered if the intraocular pressure (IOP) was 
>21mmHg on two consecutive visits.  
Main outcome measures: Intraocular pressure <22mmHg, change in ≥2 lines of Snellen visual 
acuity, and complications. 
Results: 201/204 eyes with complete data were analysed. Mean age 52 years, 17 (8.3%) eyes 
were re-treated. Mean pre-treatment IOP was 39 (SD 11) mmHg. 106 (53%) attended at 12 
months when the mean IOP was 19 (7-45) mmHg; 77 (73%) had IOP <22mmHg. Visual acuities 
were better in 13 (12.3%) and worse in 23 (21.7%) eyes. Post-operative complications included 
mild uveitis (5.5%), corneal oedema (2.5%), severe uveitis (0.5%) and transient hypotony 
(2.0%). No hypotony at 12 months.  
Conclusion: Transscleral diode laser cyclophotocoagulation controlled IOP in almost three 
quarters of eyes at 12 months with short-term preservation of vision and minimal complications. 
Poor follow-up in this setting highlights the need for an effective, safe and acceptable treatment 
where regular follow-up is less critical.  
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BACKGROUND 
Africa is the region with the highest prevalence of primary open angle glaucoma (POAG) 
affecting an estimated 7 million people aged 40-80 years.(1) The predisposition to POAG in Africa 
is likely due to variation in genetic susceptibility.(2) Glaucoma is responsible for a higher 
proportion of blindness in Africa than in other regions (range 8-22.9%)(3),(4, 5) being 16.3% in 
Nigerian adults aged 40 years and above.(6)  
There are two disease-related factors which increase the life-time risk of blindness from 
glaucoma in Africa: an earlier age of onset (7),(8) and a more aggressive course(9). In Africa, most 
people with glaucoma present very late, often blind in one eye(10,11) and there is poor awareness 
of the disease.(12,13) Services for eye care, particularly for primary eye care and specialist 
glaucoma care, are inadequate and mainly located in cities.(14,15) A high proportion of the 
population are poor and cannot afford the cost of treatment or follow-up,(16) and adherence to 
systemic or topical medication is often low.(11,17) Acceptance of glaucoma surgery is also low, 
<2% in a study in the same hospital as this case series,(11) as it does not improve visual function, 
and patients fear surgery on their only seeing eye. Although trabeculectomy can provide stable, 
long term IOP control in people of African origin,(18) ophthalmologists in Africa(19) are often 
reluctant to offer trabeculectomy for fear of complications, including visual field “wipe-out” in 
advanced cases(20) and the variable outcomes.(21-25) 
There are only a few studies comparing outcomes of surgical interventions for glaucoma 
in patients of African descent, including laser procedures.(26,27) In a recent review, the authors 
concluded that there was no evidence that any procedures are superior to trabeculectomy, and 
there is compelling evidence that the outcomes of trabeculectomy are less good than for 
Caucasian eyes, particularly if antimetabolites are not used.(28) Given the relatively low uptake of 
surgery, poor outcomes and inadequate follow-up, laser treatment could be considered as a 
primary treatment for glaucoma in Africa despite the limited reported evidence. 
In a review of 18 studies of transscleral diode laser cyclophotocoagulation as (TDLC) 
treatment, the number of eyes treated ranged from 8-263, and follow-up was 9-66 months.(29) 
The studies had different indications for treatment and often included different types of 
glaucoma. The proportion of eyes in which intraocular (IOP) was controlled (i.e. <22mmHg) 
ranged from 38% to 88.1%.(29) There are only a few studies of TDLC for seeing eyes, or as a 
primary treatment, or which were undertaken in Africa.  
With respect to studies on seeing eyes (Table 1 and 2, see Appendix), in a retrospective 
study in the UK, the indication for treatment was uncontrolled glaucoma. 46 eyes were treated, 
52% had POAG and the mean pre-treatment IOP was 24 (12-35mmHg).  At 2 years 80% of 
eyes had an IOP of <22mmHg with or without additional topical treatment: 23.9% of eyes lost 
more than two lines of VA(30). In another UK study, 49 seeing eyes were treated for uncontrolled 
glaucoma and at five years IOP was controlled (6-21mmHg) in 79.6% of eyes; 30.6% lost ≥2 
lines of VA.(31) 
Primary TDLC treatment has been reported in several studies (Table 1 and 2, see Appendix). 
For example, a study in Germany recruited individuals who refused surgery or where follow-up 
could not be guaranteed: among the 25 eyes treated, retreatment was required in 3 eyes.(51) In 
another study for a range of different types of glaucoma in Germany, 193 eyes were treated: at 
follow-up 90% of eyes with POAG had IOPs of 10-22mmHg after single or multiple 
treatments.(42)    
There are only four studies reporting TDLC treatment outcomes in Africa, from 
Cameroon,(34) Malawi,(35) Ghana(52) and Tanzania,(33) which had different indications for 
treatment, varying outcomes, small sample sizes and poor follow-up.  
The studies demonstrate that TDLC laser treatment is relatively safe, with mild post-
operative uveitis being the commonest complication (Table 1, see Appendix). Other less 
common complications, such as conjunctival or scleral burns, hyphaema, atonic pupil, choroidal 
detachment, hypotony and visual loss, which in some cases were associated with visual loss. 
Most of the more serious complications were more common in studies of patients with 
intractable or complex glaucoma. 
Given the encouraging results of TDLC in seeing eyes and the need for an acceptable 
one-off treatment in Africa, a prospective study of TDLC was undertaken for POAG in seeing 
eyes as an alternative to standard care. The purpose of the study was to explore the safety and 
effectiveness of TDLC in terms of IOP lowering, and to provide data on the rate of follow up at 
one year. All the findings will be used to design a clinical trial. The study was undertaken in a 
university teaching hospital in north-east Nigeria.  
 
PATIENTS AND METHODS 
All patients provided written informed consent for the procedure. The study adhered to 
the tenets of the Declaration of Helsinki.  
Glaucoma was diagnosed on the basis of vertical cup-disc-ratio (VCDR), IOP and visual 
field analysis, where possible. Presenting visual acuity (VA) was measured in each eye using a 
Snellen E chart and categorized using World Health Organization definitions. Consecutive new 
patients with a range of severity of POAG but who had a VA of 3/60 or better in one or both eyes 
and where surgical treatment was the treatment of choice, were recruited for primary TDLC. The 
following patients were excluded: previous glaucoma surgery, mature cataract, diabetic 
retinopathy, corneal opacities, those already bilaterally blind from glaucoma (VA <3/60), and 
those who preferred topical medication. Patients treated with TDLC for blind, painful eyes were 
also excluded. Given the lack of nomenclature for lasers in the local language the procedure 
was described in Hausa as “special computer light treatment”. Data are presented on individuals 
who had a presenting VA of 3/60 or better in the treated eye and who were followed up for 12 
months.  
TDLC treatment was performed under retrobulbar anaesthesia with lignocaine and 
adrenaline 2% in the operating theatre using the G-probe of the Iridex diode 810nm laser 
(IridexCorporation.1212 Terra Bella Avenue Mountain View, CA 94043, USA) in continuous 
mode. The probe heel was placed at the edge of the limbus matching the contour of the scleral 
curvature so that the small 0.7mm protrusion indented the sclera approximately 1.2mm 
posteriorly to optimize energy delivery to the ciliary body. Transillumination was not routinely 
used. Approximately 20 shots were delivered for 2000ms. The power was reduced by 50mW 
from the last audible pop to reduce the risk of inflammation and postoperative hyphaema.(53) 
Treatment was given over 360 degrees, avoiding the ciliary vessels at 3 and 9 o’clock, sub-
conjunctival dexamethasone 2mg was given and the eye padded for four hours. Oral diclofenac 
potassium 50mg was prescribed twice a day and G. dexamethasone 0.1% four times a day for 
one month, tailing off thereafter over a few weeks. On the first post-operative day, VA was 
measured using a Snellen E chart, patients underwent slit-lamp biomicroscopy and IOPs were 
measured using Goldmann applanation tonometry.  
Patients were reviewed at one day, one week and at one, four, six and 12 months when 
VA and IOPs were measured and anterior segments were examined at the slit lamp for 
complications. Patients were given dates for follow-up but were not actively traced. If the IOP 
was raised (>21mmHg) topical medication was initiated and if the IOP was still high at the next 
visit TDLC retreatment was offered. A second session of laser was given to those who 
consented. 
The outcomes of the study were IOP control, defined as less than 22mmHg and >30% 
IOP reduction from presenting values, measured on the day laser treatment was offered.(43,46) 
Other outcomes were change in VA, defined as at least two lines change in Snellen VA, and 
complication rates. Uveitis was defined as mild if there was anterior chamber flare, or severe if 
flare and cells were  present.   
If both eyes were treated, the first eye was the study eye. Data were entered into a 
database created in Epidata and exported into Stata/IC 14.1 statistical software (StataCorpLP 
TX 77845 USA) for analysis. Follow-up, IOP and VA findings at presentation and on the first 
postoperative day, at one week and at one, four, six and 12 months are presented. We 
calculated a Pearson’s correlation coefficient to assess the relationship between change in IOP 
and presenting IOP.  
RESULTS 
204 seeing eyes (of 204 patients) with glaucoma that had not previously had surgical or laser 
treatment underwent TDLC. 201 eyes were included in the analysis as presenting IOP data were 
missing for three. 17 (8.3%) eyes were retreated. The average power setting was 1770mW 
(range 1100-2300mW) with duration of 2000ms. The average number of laser spots was 20 
(range 15-25) per eye. 
The mean age of the 201 patients was 52 (range 12-85) years and 69% were male. The 
mean vertical cup disc ratio (VCDR) in treated eyes at presentation was 0.9 with 44% having a 
VCDR of 1.0. Visual field analysis was only possible in 65 (32%) eyes. Not all patients attended 
every follow-up appointment. A total of 106 (53%) attended at 12 months (Table 1). There were 
no differences in the age, sex or mean presenting IOP between those who attended the one 
year follow up and those who did not (Table 1).  
Table 1. Comparison between patients followed up and not followed up at one year 
 
 Followed up n=106 Not followed up n=95 
Mean age in years (range) 51 (12 to 83) 52 (14 to 85) 
Male n (%) 72 (68%) 66 (69%) 
Mean presenting IOP, mmHg (range) 38 (22 to 72) 39 (22 to 70) 
 
Intraocular pressure  
The mean IOP before treatment (201 eyes) was 39 (SD 11; range 22-72) mmHg (Table 2) and 
the median was 37 (interquartile range 29-46) mmHg. On the first postoperative day, the mean 
IOP was 12mmHg. IOPs at week one, and after one, four and six months were 11, 15, 18, 19 
and 19mmHg, respectively. At 12 months, mean IOP among the 106 (53%) patients who 
attended was 19 (range 7-45) mmHg: 72.6% (77/106) of eyes had an IOP of <22 mmHg and 
83% had a drop in IOP of >30%. The proportion of eyes on topical glaucoma medication at 
follow-up ranged from 1%-11% over the 12 months, being 9% at 12 months. Follow up of the 17 
retreated eyes was 41% (7 eyes) at 12 months. In the retreated eyes, mean IOP was 22mmHg, 
57% had an IOP of <22mmHg and two were on topical medication. 
  
Table 2: Presenting and post-operative IOP and topical medication use after TDLC 
treatment 
 
Time 
period 
Eyes 
Follow 
up 
IOP 
IOP 
<22mmHg 
On topical 
medication 
IOP drop >30% 
 N % Mean SD. Range N % N % N (%) 
Mean 
(range) % 
Presenting 201 100 39 11 22-72 201 100 0 0 0 0 
1 day 191 95 12 5 2-30 186 97.4 1 1 188 (98) -67 (-37/-94) 
1 week 177 88 11 5 1-28 170 96.1 5 3 176 (99) -68 (31-97) 
1 mon 156 78 15 7 1-48 135 86.5 15 10 144 (92) -59 (-14-97) 
4 mon 131 65 18 8 2-50 108 82.4 15 11 117 (89) -52 (-11-97) 
6 mon 118 59 19 8 3-52 89 75.4 13 11 103 (87) -51 (-23-92) 
12 mon 106 53 19 7 7-45 77 72.6 10 9 88 (83) -48 ( -7-87) 
mon =months 
There was a strong correlation between change in IOP between presentation and follow 
up at 12 months, and presenting IOP (correlation coefficient 0.44, p<0.001)(Figure 1). 
 
Figure 1. Scatterplot of change in IOP between presentation and follow up at 12 months, 
and presenting IOP in 106 eyes. 
There was no significant associations between presenting and final IOP with the laser 
energy used nor the number of laser spots delivered. There were no age or gender differences 
in IOP at presentation or at 12 months.   
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The majority of eyes (83/106, 78%) either retained their presenting VA (70, 66%) or the VA had 
improved by two or more lines at 12 months (13, 12%). Visual acuity deteriorated by two or more 
lines in 23 eyes (22%): these eyes had slightly higher pre-treatment IOPs (mean 41; range 26-
72 mmHg) than those not losing VA (mean 37; range 22-60 mmHg). At 12 months the mean IOP 
in the eyes that lost VA was 29 (range 8-45) mmHg compared with 19 (range 7-30) mmHg in 
eyes with stable VA. In addition, 12 (52%) eyes losing VA had a pre-treatment VCDR of 1.0 
compared with 28 (39%) of eyes not losing VA. Four eyes losing VA had progression of cataract, 
and six had corneal oedema before TDLC which persisted after treatment. There were no new 
cases of corneal oedema. Visual loss in the remaining eyes was attributable to glaucoma 
progression.   
Safety and complications 
A few patients had mild anterior uveitis on the first postoperative day, which resolved with topical 
steroids (Table 3). No eyes developed hyphaema or other serious complications. Transient 
hypotony (IOP <6 mmHg), developed in four eyes during follow-up but no eyes had hypotony at 
12 months. Eyes that were retreated had slightly higher complication rates, with one eye 
developing severe uveitis. 
 
Table 3. Complications after first and second treatment with transscleral diode laser 
cyclophotocoagulation 
 
Complications 
First treatment  Second treatment  
(201 eyes) (17 eyes) 
  N % N % 
Mild anterior uveitis 11 5.5% 2 11.8 
Severe uveitis 1 0.5% 1 5.9 
Hypotony (<6mmHg) - temporary 4 2.0% 0 0 
Hypotony (<6mmHg) - persistent 0 0.0% 0 0 
Corneal oedema 5 2.5% 1 5.9 
Cataract progression 4 2.0% 0 0 
 
  
DISCUSSION  
This is the largest case series of TDLC as a primary treatment for seeing glaucomatous eyes in 
Africa. Unlike other studies from Africa the inclusion criteria were clearly defined, as were the 
outcomes. A standard treatment protocol was used and one ophthalmologist who had been 
trained in TDLC in the United Kingdom treated all the patients. TDLC was effective at attaining 
IOP <22mmHg in a high proportion of treated eyes with follow up data at 12 months, the majority 
not requiring additional treatment, with good preservation of VA in the short term. Our study 
suggests that the proportion of eyes with an IOP <22mmHg is a better outcome measure in this 
population, where values at presentation were high, than the proportion achieving >30% 
reduction in IOP.  
Our findings need to be considered in the context of the glaucoma patients who present 
to ABTUTH most of whom have advanced glaucoma i.e., they rarely accept incisional surgery 
nor adhere to topical medication or regular follow-up after surgery. Laser treatment was, 
therefore, offered to patients where it was considered the only viable alternative. As in other 
TDLC studies, immediate post-treatment complications were minimal, but were slightly higher in 
retreated eyes.   
There was good acceptance of TDLC, which may be explained by the term used to 
describe it, which avoided the local Hausa term for surgery, “fidar ido”, which means 
“butchering”. TDLC was described as a once-off, but repeatable treatment, which is desirable in 
settings where there is a fear of surgery and hospitalization, and a culture of not attending 
follow-up. For service providers TDLC is easy to learn and the solid-state laser used is cheaper, 
and more reliable and versatile than other lasers. 
Poor follow-up is a challenge in glaucoma care in Africa, as in this study, where patients either 
did not return for follow-up at all, or did so at irregular intervals. Despite this, in our study over 
half returned at 12 months which was a marked improvement from an earlier study in the same 
hospital.(11) Retreated eyes had poorer follow up and poorer IOP control than eyes that were not 
retreated. However, poor follow-up may have biased the findings, since those who did not return 
may have lost vision and hence faith in the service. However, patients in whom vision had 
stabilised or improved may have failed to return, believing that they were ‘cured’. Poor follow-up 
emphasizes the need in rural Africa for a procedure that maintains IOP control, which has few 
postoperative complications and where regular follow-up is less critical.  
Comparison of our findings with other studies from Africa is difficult given the variation in 
study designs, indications for and methods of treatment, outcome definitions and follow-up rates. 
For example, the study in Ghana was a clinical trial to assess different laser power settings. 
Treatment was offered as a primary treatment and 92 eyes were treated: at three months 38 of 
the 79 patients who attended (48%) had an IOP of 22mmHg or less; 16 of these eyes had been 
retreated and topical medication was being used in 68 eyes.(52) The study in Tanzania was a 
retrospective review of 179 treated eyes only 49 of whom had at least one follow-up visit. At the 
3-6 month follow-up 4/12 eyes had an IOP of ≤21mmHg and 9 eyes were retreated.(33) The study 
in Cameroon used a 910nm laser (not the usual 810nm laser) to treat 272 eyes but only 26 
(<10%) attended at 12 months when the average IOP reduction was 7.5 mmHg i.e., lower than 
in our study.(34) In the Malawi study, a low dose of 900mW was used to treat POAG and 
pseudoexfoliative glaucoma. At 3 months mean IOP had fallen from 38.5 to 35.6mmHg. In 50% 
of treated eyes the IOP returned to pre-treatment levels.(35) These poor outcomes are probably 
explained by the low power setting used. In the present study IOP control was defined an IOP of 
<22 mmHg, a target used in other studies. However, the natural history and optimal target IOP 
to control glaucoma in Africa is not known. 
Most glaucoma patients of African ancestry lose vision rapidly if they are not treated or 
have poor IOP control.(54) In our study the majority of treated eyes either maintained their 
presenting VA or their acuity improved. The latter has been reported before.(55) The majority of 
patients lost vision from progression of age related conditions such as cataract, or progression of 
glaucoma in end-stage eyes, rather than as a direct result of the procedure. 
Complications following treatment were minimal in the present study, and compared well 
with other studies on seeing eyes, but severe uveitis was higher following retreatment, but 
numbers are small. TDLC has had a relatively bad press in industrialized countries, probably 
because it is usually offered as the treatment of last resort. Failure rates and high complications 
rates are much more likely in these eyes.49  
A limitation of this study was that visual fields, vertical cup:disc ratios and other 
parameters were not used to monitor disease progression. There are several reasons for this.  
Firstly, reliable assessment of visual fields is very difficult amongst uneducated African patients, 
as many have extensive visual field loss and are not familiar with interacting with technology. 
Second, many patients had corneal oedema at presentation, which prevented optic disc imaging 
at presentation, and lastly, optical coherence tomography was not available, which would have 
provided objective data to monitor structural changes at the optic nerve head. However, 
monitoring optic disc change in eyes with very advanced disease would be challenging, as in the 
present study, where almost half the eyes had a cup:disc ratio of 1.0 before treatment.  
The findings of the present study may be generalisable to other parts of Africa where 
challenges faced by most glaucoma patients are similar. TDLC appeared to be acceptable, 
provided reasonable IOP control after one or two sessions and preserved vision at least in the 
short term for patients who would otherwise be without treatment. 
Implications for service delivery / research 
TDLC is a simple, quick and minimally-invasive and could be delivered by general 
ophthalmologists as a primary treatment(56) or as an alternative to surgery in low-income 
settings.(37) The low cost, acceptability and ease of delivering TDLC, offers some promise in the 
otherwise bleak landscape of glaucoma care in Africa. Given that a once-off treatment is the 
desired approach to glaucoma control in Africa, and that acceptance of trabeculectomy 
(standard of care)(11,19) is very low in our setting, clinical trials are needed to compare the 
effectiveness, acceptability, cost and safety of other forms of laser treatment as a primary 
treatment for glaucoma. These trials need to use standard definitions of control in terms of IOP 
lowering, together with robust methods to assess disease progression in terms of functional and 
structural parameters, although the latter will be challenging in this setting, requiring objective 
methods such as serial optic disc imaging. The sample size calculation will need to take account 
of loss to follow up, after pilot testing different approaches to maintain follow up, such as 
reimbursement of travel expenses, and fast tracking on arrival at the eye clinic.  
CONCLUSIONS 
TDLC controlled IOP in almost three quarters of eyes at 12 months among the 50% of patients 
who were followed up, with short-term preservation of vision and minimal complications. Poor 
follow-up in this setting highlights the need for an effective, safe and acceptable treatment where 
regular follow-up is less critical. Randomized clinical trials of TDLC in Africa are warranted. 
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APPENDIX 
Table 1. Transscleral diode laser cyclophotocoagulation treatment studies: indications for and methods of treatment, participants and 
outcome measures 
 
Author, country 
(ref) 
Study design Type of glaucoma Indications for treatment 
Number 
treated 
Definition of 
outcome 
Preoperative IOP 
(mmHg) (range) 
Studies in Africa  
Egbert, 
Ghana(32) 
Trial of laser 
power 
POAG Primary treatment 92 eyes Final IOP <22 mm 
Hg 
Mean 29.3 (16-
66)mmHg 
Mavrakanas, 
Tanzania(33) 
CS: retro-
spective 
POAG (seeing and 
non seeing) 
Uncontrolled IOP 49 eyes Lower IOP Mean 53mmHg 
Preussner, 
Cameroon(34) 
CS - 
prospective 
using 910nm 
laser  
POAG IOP reduction; reduction in 
medication  
272 eyes; 
26 followed 
up 
IOP reduction at 1 
year 
Mean 31.2mmHg 
Schulze, 
Malawi(35) 
CS: prospective POAG; PXE  IOP reduction 47 eyes Mean IOP 
reduction 
Mean 38.5mmHg 
Studies in other countries  
Rotchford, UK(31) CS: retro-
spective  
POAG seeing eyes Primary treatment 49 eyes Loss of 2 or more 
VA line IOP 8-21 
28mmHg (16-50) 
Ghosh, UK(30) CS: prospective POAG seeing eyes High IOP 
 
46 eyes At 24 months  Mean 24mmHg 
Kuchar, USA(36) CS: prospective 
(micropulse 
laser) 
Advanced  Uncontrolled IOP 19 eyes 6-21 mmHg/20% 
lower at last visit  
Mean 37.9 mmHg  
Butt, Pakistan(37)  Quasi-
experimental  
POAG  POAG on maximum 
medication; Primary Rx 
60 eyes IOP reduction  Mean 41.62 (28 – 
60) mm Hg 
Bloom, UK(38)  CS: prospective. 
YAG laser 
Any type Refractory glaucoma after 
multiple procedures 
45 eyes Not defined Mean 32mmHg 
Ansari, UK(39) CS: retro-
spective 
Non refractory  Poor control; painful, blind 
eye allergies; refused 
surgery;  
74 eyes Lower IOP fewer  
medications 
Mean 40.3mmHg 
Spencer, UK(40) CS: prospective Refractory  Uncontrolled IOP: surgery 
refused or unlikely 
58 eyes Fewer glaucoma 
mediccations 
Mean 33.0 mmHg 
Martin, UK(41) CS: prospective Painful blind eyes Pain 30 eyes IOP reduction; pain 
relief 
Mean 51 mm Hg 
Kramp, 
Germany(42)  
CS: retro-
spective 
109 POAG;  84 
secondary  
Uncontrolled glaucoma 193 eyes IOP 10-22 mmHg  Mean 24.6+/-6.7 
mmHg 
Murphy, UK(43) CS: retro-
spective 
Refractory: 46% 
neovascular  
Uncontrolled glaucoma 263 eyes IOP <22 mm Hg or 
> 30% drop in IOP 
Mean 40.7 mmHg 
Lai, Hong 
Kong(44)  
CS: prospective CACG Medical uncontrolled CACG 13 eyes IOP <21mmHg 
with or without 
medication 
Mean 36.4 +/- 12.6 
mm Hg  
Grueb, 
Switzerland(45) 
CS: retro-
spective 
POAG, PXEG POAG, PXEG 90 eyes 4-18mmHg or 20% 
reduction 
Mean 21 mmHg 
(12–36 mmHg) 
Vernon, UK(46) CS: retro-
spective 
Refractory; 19%  
19%  
Poor control 42 eyes IOP<22; reduction 
in medicine 
Mean 31.4mmHg 
Iliev, 
Switzerland(47) 
CS: retro-
spective 
Advanced, 
refractory: 3% 
POAG; 61% 
neovascular  
Refractory glaucoma 131 eyes IOP 6-21 at last 
visit 
Mean IOP 
36.9mmHg  
Raivio, 
Finland(48) 
CS: retro-
spective 
1/3 PXE; POAG/ 
complex  
Poor control; refractory 
glaucoma 
60 eyes 8-21mmHg IOP  27 ± 11 mmHg 
Frezzoti, Italy(49) CS: prospective Advanced/refractor
y: 36% POAG; 
64% complicated  
Refractory 124 eyes IOP 5-21; pain 
relief 
Mean 29.9 +/- 8.4 
mmHg (17-58 
mmHg) 
Zhekov, UK(50) CS: retro-
spective 
Refractory. One 
treatment only.  
45 POAG/PACG 
IOP maintained; visual 
acuity 
87 patients Not defined IOP 39.5mmHg 
 
CS = case series; IOP = intraocular pressure; POAG = primary open angle glaucoma; PXEG = primary exfoliative glaucoma; CACG = chronic 
angle closure glaucoma  
  
Table 2. Transscleral diode laser cyclophotocoagulation treatment studies: outcome of treatment and complications  
 Follow-up 
Outcome: 
Post op IOP 
Outcome:  
Visual acuity (change) 
Complications  
(n) Number of eyes 
Comments 
Studies in Africa   
Egbert (32) Mean 13.2 
months  
≥20%mmHg drop in 47%; 48% 
final IOP <22 mm Hg  
Worse in 23% but not 
defined 
Atonic pupil (92) 28%; transient 
hyphaema (3), severe iritis (2). No 
hypotony, phthisis or sympathetic 
ophthalmia. 
 
Mavrakanas 
(33) 
Variable  At last visit 51% eyes had 
>50% lower IOP 
Not reported No serious complications  
Preussner(34
) 
1 year, 26 
eyes 
Mean reduction: 7.5mmHg Not reported No serious complications Medication reduced 
from 1.5 to 1.2.  
Schulze(35) 3 months Mean 35.6mmHg Not reported Atonic pupil (4) 10.6%; transient iritis 
(1) (2.1%) 
Low dose diode used 
Studies in other countries   
Rotchford(31) 5 years 79.6% controlled at final follow-
up 
≥2 lines: worse 30.6% (15 
eyes): 9 glaucoma 
progression. 
Vitreous haemorrhage (1); retinal 
detachment (1); macula oedema (4) 
 
Ghosh(30) 24 months Mean 17.2 (12-28);  
84.8% IOP<21mmHg 
>2 lines: same 76.1%; 
worse 23.9%; (11 eyes); 9 
glaucoma progression.  
Macula hole (1); retinal detachment 
(1); macula oedema (2). No hypotony.  
 
Kuchar(36) Mean 60.3 
days  
22.7 mmHg at last follow-up, 
40.1 % decrease. 
One line of VA: better 21%; 
worse 21%.  
Hypotony (1).  
Butt(37)  12 months Mean 15mmHg at 6 mon; 
14.15mmHg at 1 year 
Not reported Anterior uveitis, cataract (8) 13.3% 
each; hyphaemia (5) 8.3%; hypotony 
(6) 10%  
45% of eyes 
retreated. 6% had 
three treatments.   
Bloom(38)  No data Mean 19.3mmHg. 
71% treatment success 
≥2 lines: worse 9% Phthisis (1); chronic hypotony (2); 
hyphaema and vitreous haemorrhage 
(1) 
 
Ansari(39) 12.5 (4–30) 
months 
Mean: reduced by 45.1% to 
21.1 mmHg at final visit. 
Mean VA preserved in 
those with good VA; worse 
in 13% (glaucoma 
progression; lens opacity, 
chronic uveitis) 
Hyphaemia (3); chronic iritis (3); 
corneal oedema (1). No hypotony or 
other serious complications. 
58% reduction in 
medication. All with 
iritis had peripheral 
iridectomy 
Spencer(40) Mean 19 (6-
37) months 
Mean 16.7 mm Hg at final visit  >2 lines: worse 32%  Rubeotic eye developed 
endophthalmitis. Chronic hypotony (2) 
no phthisis (8) 13.3% 
Fewer medications: 
from 2.4 to 1.4. Up to 
5 treatment sessions 
Martin(41) 6 months 26 mm Hg. Pain relief in 73.3%  Not reported Hypotony (3); phthisis (1); uveitis (2); 
hyphaema (1) 
 
Kramp(42) Mean 13.9 (6 
to 48) 
months 
Success 76.4%. Mean 19.3+/-
5.7 mmHg. Best results in 
POAG 
No reported Mild anterior uveitis (31); hyphaema 
(1); phthisis bulbi (3)  
≤6 sessions. 2 
phthisical eyes had 
neovascular 
glaucoma and PXG 
Murphy(43) 17 months 
(6-46) 
Mean 17.7 mmHg. Reduction 
of 52.6%. Success 89% 
Not reported Hypotony ranged from 0% in POAG 
to 18.8% in uveitic glaucoma. 
Persistent uveitis 1.6%: most in 
complicated glaucoma 
A third of eyes were 
retreated 
Lai(44)  Mean 26.5 
(+/- 4.2) 
months 
Success 92.3%. Mean 18.7 +/- 
12.2 mm Hg at final visit 
≥2 lines: same 15.4%; 
better 46.2%; worse (5 
eyes). 
No hypotony. Atonic pupil (7)  
Grueb(45) ≥24 months Mean 16 (9–27) mmHg. 
Success 36.7% all 
40.9% POAG 
Not reported Hyphaema (1); anterior uveitis (10). 
No phthisis. 
 
Vernon(46) Mean 65.7 
(36-84) 
months 
88.1% success. 50.3% 
reduction in IOP. Mean 15.6 +/- 
6.3 mmHg 
Same 26.2%  
Better 9.5%  
Worse 64.3%   
Transient hypotony (2) Fewer medications: 
from 2.6 to 1.7. ≤6 
sessions. Focus on 
maintaining acuity 
Iliev(47) Mean 30 
months (no 
range)  
Success in 69.5%. 45.8% IOP 
controlled with 1 treatment 
Not reported Hypotony (23) 17.6%. 74% of these 
eyes had neovascular glaucoma. 
Chronic uveitis (1); severe dry eye 
(1); hyphaema (1) vitreous 
haemorrhage (1). 
Fewer medications: 
mean from 2.97 to 
1.39. Multiple eyes 
were retreated.  
Raivio(48) 26 (3–75) 
months 
18±5mmHg at 6months,  
19±7mmHg at 1year, 
80% had 30% reduction in IOP 
at last follow-up 
Not reported Mild anterior uveitis 25%; hyphaema 
(2 eyes), vitreous haemorrhage (1). 
No hypotony. 
 
Frezzoti(49) 17 (3-42) 
months 
20.8mmHg (range 6-45) last 
visit 
Loss of two or more lines: 
12.9% 
Mild anterior uveitis (3) 2.4%; 
hypaema (2) 1.6%. No hypotony or 
phthisis 
 
Zhekov(50) 3 years 17.8mmHg at 6 weeks 
maintained over 3 years 
Same or better: 83.6% Hypotony 5%; no uveitis  
IOP = intraocular pressure 
 
 
 
 
 
 
 
 
 
 
 
